Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14693601 | 0.85 | RAB9A (0.45) | XDHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14693600 | 0.84 | XDH (0.46) | XDHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5819432 | 0.82 | XDH (0.43) | XDHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3124098 | 0.81 | XDH (0.53) | XDHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2969443 | 0.79 | SRC (0.46) | XDHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL24096486 | 0.78 | SRC (0.50) | XDHPIK3CDPIK3CBPIK3CGSRC | |
| SCHEMBL4828333 | 0.77 | SRC (0.47) | XDHPIK3CGSRCEGFRMEN1 | |
| SCHEMBL13201536 | 0.77 | SRC (0.47) | XDHPIK3CGSRCEGFRNPC1 | |
| SCHEMBL15708517 | 0.77 | XDH (0.52) | XDHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14617846 | 0.75 | EGFR (0.60) | XDHPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975082-B2 | Inhibitor of FLT3 kinase and use thereof | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2021-04-13 | — | — | US | disclosed |
| EP-3466952-B1 | 1-(4-(4-AMINO-3-PHENYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)-PHENYL)-UREA DERIVATIVES AS FLT3 KINASE INHIBITORS FOR TREATING CANCER | PRECEDO PHARMACEUTICALS CO LTD (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3466952-A1 | NOVEL INHIBITOR FOR FLT3 KINASE AND USES THEREOF | Precedo Pharmaceuticals Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017206962-A1 | NOVEL INHIBITOR FOR FLT3 KINASE AND USES THEREOF | 合肥中科普瑞昇生物医药科技有限公司 | 2017-12-07 | — | — | WO | disclosed |
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975082-B2 | Inhibitor of FLT3 kinase and use thereof | FLT3, FLT1, FGFR1 | XDH 1233/4885PIK3CD 339/4885PIK3CA 115/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | XDH 484/4885PIK3CD 1497/4885PIK3CA 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.